⌘K
Loading ticker…
As of 2026-08-24, Immix Biopharma, Inc. Common Stock (IMMX) has a 3-month relative strength percentile of 95 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 93. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 7.6%, relative volume 0.93×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
IMMX is in a stage 2 uptrend, week 3. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 34.2% / 69.4%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
IMMX appears in 1 ETF as of May 2026: AVSC at 0.00% weight, $78K notional.
Held by 4 ETFs · $16M across latest filings · largest weight 0.01% (IWC).
Top 1 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| AVSC | 0.00% | $78K | new |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | IMMX Jan avg: -7.90% median: -0.17% win: 50% σ: 27.15% n: 4 2022-04-12 → 2026-07-31 | IMMX Feb avg: -0.53% median: -10.28% win: 25% σ: 26.42% n: 4 2022-04-12 → 2026-07-31 | IMMX Mar avg: -3.40% median: -6.99% win: 25% σ: 11.22% n: 4 2022-04-12 → 2026-07-31 | IMMX Apr avg: 1.96% median: -1.98% win: 40% σ: 28.21% n: 5 2022-04-12 → 2026-07-31 | IMMX May avg: 9.16% median: 0.78% win: 60% σ: 27.72% n: 5 2022-04-12 → 2026-07-31 | IMMX Jun avg: 10.30% median: 14.56% win: 60% σ: 18.80% n: 5 2022-04-12 → 2026-07-31 | IMMX Jul avg: -2.59% median: -6.15% win: 40% σ: 21.98% n: 5 2022-04-12 → 2026-07-31 | IMMX Aug avg: -10.47% median: -9.92% win: 25% σ: 13.65% n: 4 2022-04-12 → 2026-07-31 (current) | IMMX Sep avg: 1.74% median: -15.57% win: 25% σ: 45.72% n: 4 2022-04-12 → 2026-07-31 | IMMX Oct avg: 17.14% median: 6.62% win: 75% σ: 45.85% n: 4 2022-04-12 → 2026-07-31 | IMMX Nov avg: 26.47% median: 26.44% win: 100% σ: 12.77% n: 4 2022-04-12 → 2026-07-31 | IMMX Dec avg: 38.00% median: 29.24% win: 100% σ: 36.49% n: 4 2022-04-12 → 2026-07-31 |